<DOC>
	<DOCNO>NCT01159171</DOCNO>
	<brief_summary>This study ass efficacy safety treatment combination Avastin ( bevacizumab ) 5mg/kg iv every 2 week , Xeloda ( capecitabine ) 1000 mg po b.i.d . Days 1-14 every 28-day cycle oxaliplatin 40mg/m2 iv weekly patient inoperable locally advanced metastatic colorectal cancer . The anticipated time study treatment disease progression .</brief_summary>
	<brief_title>A Study Avastin ( Bevacizumab ) Oxaliplatin Plus Xeloda ( Capecitabine ) Patients With Advanced Colorectal Cancer .</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>Adult patient &gt; =18 year age Locally advance metastatic colorectal cancer No previous treatment chemotherapy metastatic disease Measurable and/or evaluable lesion Radiotherapy within 4 week study Untreated brain metastasis primary brain tumor Chronic , daily treatment highdose aspirin ( &gt; 325mg/day ) Coexisting malignancy , malignancy diagnose within last 5 year , exception basal squamous cell cancer , cervical cancer situ</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>